A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
RSS SUMMARY · AGGREGATED FROM CNBC
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
Continue Reading
The full story continues on CNBC.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
CNBC
Business
Why Trump reversed course to fast-track psychedelic drugs for mental healthcare
CNBC·1h ago·3 min read
Business
Disney is poised to ramp its already booming advertising business. Rita Ferro is behind the push
CNBC·3h ago·3 min read
US
DOJ seeks Judge Eleanor Ross recusal in Georgia election case, citing reports she was disciplined
CNBC·19h ago·3 min read
US
Meta has struggled at selling anything other than ads. Will AI be different?
CNBC·1d ago·3 min read
Related
On this beat
Business
Morgan Stanley revisits NetApp stock price target after earnings
THE STREET·1h ago·3 min read
Business
Micron, SanDisk get a number Wall Street rarely writes
THE STREET·1h ago·3 min read
Business
Wall Street bulls bet US stocks rally will defy bubble fears
FT·1h ago·3 min read
Business
We moved to Japan 3 years ago. We have a lower cost of living and travel more.
BI·46m ago·3 min read